FFA
VRTX icon

Freedman Financial Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Freedman Financial Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-48
Closed -$13K – 417
2022
Q1 		$13K Hold
48
– – 0.01% 334
2021
Q4 		$11K Hold
48
– – 0.01% 337
2021
Q3 		$9K Hold
48
– – 0.01% 358
2021
Q2 		$10K Hold
48
– – 0.01% 346
2021
Q1 		$10K Buy
+48
New +$10.5K 0.01% 357

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Freedman Financial Associates's VRTX Position: Q2 2022 in Review

Freedman Financial Associates sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 48 shares — an estimated $13K sold.

Freedman Financial Associates first reported a position in VRTX in Q1 2021 and held it in 5 quarters. The position peaked at $13K in Q1 2022. 1,106 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

  • Freedman Financial Associates reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Freedman Financial Associates sold 48 Vertex Pharmaceuticals shares in Q2 2022, an estimated $13K.
  • Freedman Financial Associates first reported a position in Vertex Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • Freedman Financial Associates's Vertex Pharmaceuticals position peaked at $13K in Q1 2022.
  • 1,106 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Freedman Financial Associates's 13F filing for Q2 2022.